Intellia Therapeutics, Inc. (NTLA) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Intellia Therapeutics (NTLA) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. NTLA is a clinical-stage CRISPR gene-editing biotech whose thesis rests on its in vivo platform, which edits genes directly inside the body, and two late-stage candidates: lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis, the latter partnered with Regeneron. The FDA has accepted lonvo-z for Priority Review with a decision date of March 10, 2027, and the stock closed at about $11.19 on October 16, 2026 (market cap about $1.6 billion), up about 22% year to date but down about 55% over one year. The biggest risk is that the company is pre-revenue and unprofitable, its value is tied to binary clinical-trial and regulatory outcomes, and it funds operations through cash reserves that periodically require dilutive equity raises.

NTLA stock price

As of 2026-11-16, Intellia Therapeutics, Inc. (NTLA) last closed at $9.86, up 16.3% over the past year. Over the past 52 weeks it has traded between $8.04 and $17.84.

NTLA last close
$9.86
1 day
+1.65%
1 month
-13.66%
1 year
+16.27%
52-week range
$8.04 to $17.84
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Intellia Therapeutics, Inc.'s investor relations page. Walnut is informational, not investment advice.

NTLA key stats

At $9.86 on November 16, 2026, Intellia Therapeutics, Inc. (NTLA) has a market cap of $1.4B.

Market cap
$1.4B
Price to book
2.3
Beta
1.82

Market cap, P/E and yield are measured at the $9.86 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Intellia Therapeutics, Inc. (NTLA)?

The last two weeks for Intellia Therapeutics, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NTLA closed at $9.86 on November 16, 2026, down 18.6% over the past five trading days (from $12.11).
  • On November 13, 2026, Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting an amendment about information shared with investors (Regulation FD) (Item 7.01). Read the 8-K on sec.gov
  • On November 12, 2026, Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 5, 2026, Intellia Therapeutics, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
  • On November 5, 2026, Intellia Therapeutics, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Intellia Therapeutics, Inc. (NTLA) latest quarter

Intellia Therapeutics reported revenue of $7.2 million for Q3 2026, down 48% from a year earlier (Intellia Therapeutics, Nov 5, 2026).

Revenue
$7.2 million
down 48% from a year earlier
Diluted EPS
-$0.91
n/a
ATTR co-development and co-promotion agreement
$6.8 million
down 19% from a year earlier

Source: Intellia Therapeutics Q3 2026 results, Nov 5, 2026. Full earnings breakdown

What does Intellia Therapeutics, Inc. (NTLA) do?

Intellia Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, developing genome-editing therapies based on CRISPR/Cas9. Its core differentiator is a proprietary in vivo platform that delivers the editing machinery directly into the body, typically the liver, using lipid nanoparticles, so that a single dose can permanently inactivate or modify a disease-causing gene without removing cells from the patient. This contrasts with ex vivo approaches that edit cells outside the body and reinfuse them. The company is pre-revenue from products and currently records only collaboration revenue from partners; it funds operations through its cash reserves and periodic capital raises.

Intellia was co-founded in 2014, drawing on foundational CRISPR research associated with Nobel laureate Jennifer Doudna, and went public on the Nasdaq in 2016. Its two most advanced wholly described programs are lonvoguran ziclumeran (lonvo-z, formerly NTLA-2002) for hereditary angioedema and nexiguran ziclumeran (nex-z, formerly NTLA-2001) for transthyretin (ATTR) amyloidosis, the latter developed in collaboration with Regeneron Pharmaceuticals. In 2025 the company prioritized these late-stage assets through a strategic reorganization. By mid-2026, lonvo-z had reported positive Phase 3 HAELO results and completed its biologics license application, while the nex-z Phase 3 MAGNITUDE and MAGNITUDE-2 trials in ATTR were advancing after the FDA lifted earlier clinical holds.

Since then the story has moved from data to regulators and financing. As of October 2026, the FDA had accepted the lonvo-z application under Priority Review with a target action date of March 10, 2027, which would make it the company's first potential product launch. In September 2026 Intellia secured a debt facility of up to $400 million from OrbiMed, with $75 million drawn upfront, adding non-dilutive capital to the ~$207 million April equity raise, and in October it named Jing L. Marantz, M.D., Ph.D., as Chief Medical Officer. Financially, the second quarter of 2026 brought collaboration revenue of about $7.7 million and a net loss of about $107 million (EPS of -$0.80 against a -$0.78 estimate). The shares closed at about $11.19 on October 16, 2026, up about 22% year to date but down about 55% from a year earlier, inside a 52-week range of about $7.95 to $28.25. Analyst views are split: the 18 covering analysts' mean target is about $23, while Barclays started coverage on October 6 at underweight with an $8 target. The next quarterly report is expected around November 5, 2026.

What's driving Intellia Therapeutics, Inc. (NTLA)?

Positive Late-Stage Lonvo-z Data in Hereditary Angioedema

In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. The data were published in the New England Journal of Medicine and presented at EAACI 2026. The FDA has since accepted the biologics license application under Priority Review, with a decision date of March 10, 2027, positioning lonvo-z as a potential one-time treatment with a possible U.S. launch in 2027.

In Vivo CRISPR Platform

Intellia's central asset is its in vivo editing platform, which aims to make a single-dose, durable genetic change inside the patient's body rather than through cells edited in a lab. If validated across multiple programs, this approach could be applied to a range of genetic and acquired diseases. The same delivery and editing technology underlies both lead candidates, so platform validation in one indication carries read-through to the broader pipeline.

Regeneron Partnership and Nex-z in ATTR Amyloidosis

The nex-z program for ATTR amyloidosis is developed with Regeneron Pharmaceuticals, which shares development costs and provides a large-pharma partner. In early 2026 the FDA lifted clinical holds on the Phase 3 MAGNITUDE (cardiomyopathy) and MAGNITUDE-2 (polyneuropathy) trials, with MAGNITUDE-2 enrollment targeted for the second half of 2026. ATTR amyloidosis is a large and growing market currently served by approved stabilizer and silencer drugs from other companies.

Large Addressable Disease Areas

Both lead programs target serious diseases with meaningful patient populations and high unmet need where a single-dose therapy could be differentiated from chronic treatments. Hereditary angioedema patients currently rely on lifelong prophylaxis, and ATTR amyloidosis is an underdiagnosed, progressive condition. A durable one-time editing approach, if approved and adopted, could address both the clinical burden and the cumulative cost of chronic therapy, though commercial success is not assured.

What are the risks to Intellia Therapeutics, Inc. (NTLA)?

Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The company loses roughly $95 million to $107 million per quarter (about $400 million over the trailing twelve months to June 2026) and has repeatedly raised equity to extend its runway, so existing shareholders face ongoing dilution risk before any product profit materializes. The September 2026 OrbiMed facility of up to $400 million reduces near-term reliance on equity but adds debt that must be serviced and repaid. A launch, if lonvo-z is approved, also brings new spending on a commercial organization before revenue arrives, and collaboration revenue has been shrinking (about $7.7 million in Q2 2026, down about 46% year over year). Even with positive data, regulatory approval, reimbursement, and commercial adoption of a novel one-time gene-editing therapy are uncertain and could take years. The company also competes with better-capitalized CRISPR and gene-editing peers, with RNA-interference and stabilizer drugs already approved in ATTR, and with established prophylaxis options in hereditary angioedema.

What is the Intellia Therapeutics, Inc. (NTLA) forecast?

18 analysts publish price targets on NTLA, averaging $22.78 as of November 2026, or +131.0% against the $9.86 share price on November 16, 2026. The published targets run from $8.00 to $61.00, a wide spread, and the ratings split 10 buy, 6 hold, 4 sell. Over the last six months there have been 3 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NTLA forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is NTLA a buy or a sell?

We give no verdict on Intellia Therapeutics, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Positive Late-Stage Lonvo-z Data in Hereditary Angioedema. In 2026 Intellia reported positive Phase 3 HAELO results for lonvo-z in hereditary angioedema, including an approximately 87 percent reduction in mean monthly attacks versus placebo, with a majority of treated patients reported as attack-free over the efficacy period. The most optimistic published target, $61.00, assumes this works close to its best case.

The case against. Intellia is pre-revenue from products, deeply unprofitable, and its value depends on binary clinical and regulatory outcomes; a single failed trial, safety signal, or FDA setback for lonvo-z or nex-z could sharply reduce the stock's value. The most pessimistic target, $8.00, is roughly what NTLA is worth if this bites instead.

Read the full bull and bear case on NTLA, including what would have to change to break either one. Walnut is not an investment adviser.

Has Intellia Therapeutics, Inc. (NTLA) split its stock?

No. Intellia Therapeutics, Inc. (NTLA) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Intellia Therapeutics, Inc. (NTLA) valued?

Market cap, P/E and dividend yield at today's price are in the NTLA key stats above. The business figures below come from Intellia Therapeutics, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM to June 2026): ~$60M collaboration revenue; Q2 2026 ~$7.7M (-46% YoY)
  • Net loss (TTM): ~$400M; Q2 2026 ~$107M
  • Cash / debt: ~$438M cash and short-term investments, ~$73M debt (June 2026)
  • New financing: OrbiMed debt facility up to $400M, $75M upfront (Sept 2026)

As of October 2026: Because Intellia has no product profits and only collaboration revenue, earnings-based multiples like P/E are negative and not analytically useful; at about $1.57 billion the market value sits at roughly 2 times book. The stock is better evaluated on its cash runway relative to a trailing operating cash outflow of about $347 million, the probability and timing of approval for lonvo-z (FDA decision due March 10, 2027) and nex-z, and the risk-adjusted commercial potential of those programs. The April 2026 equity raise and the September 2026 OrbiMed debt facility extend the runway, but pre-profit biotechs of this type typically require additional capital before reaching sustained profitability, so dilution and the binary nature of regulatory and trial outcomes stay central to any valuation view.

What themes does Intellia Therapeutics, Inc. (NTLA) fit?

These are the investment theses NTLA naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Intellia Therapeutics, Inc. (NTLA)?

Pure-Play CRISPR Gene-Editing Companies

CRISPR Therapeutics (CRSP) is the most directly comparable peer and the only CRISPR-focused biotech with an approved product, Casgevy, co-developed with Vertex for sickle cell disease and beta-thalassemia; it held roughly $2.4 billion in cash as of early 2026, a stronger balance sheet than Intellia. Editas Medicine (EDIT) is a smaller founding-era CRISPR peer that has refocused on in vivo development candidates. These companies share Intellia's foundational ambition and compete for capital, talent, and clinical priority.

Base Editing and Next-Generation Editing Platforms

Beam Therapeutics (BEAM) pursues base editing, a CRISPR variant that makes single-nucleotide changes without cutting both DNA strands, and held roughly $1.2 billion in cash as of early 2026 while advancing programs in sickle cell disease and other rare conditions. Prime Medicine develops prime editing for precise gene correction. These platforms compete for the same disease targets and investor attention, though none has yet reached commercial approval.

Established Therapies in Intellia's Target Indications

In ATTR amyloidosis, nex-z must eventually compete with already-approved chronic therapies, including RNA-interference drugs from Alnylam Pharmaceuticals and stabilizer drugs such as tafamidis from Pfizer and acoramidis from BridgeBio. In hereditary angioedema, lonvo-z would enter a market with established prophylaxis options from companies such as Takeda and CSL. A one-time editing therapy must demonstrate a compelling advantage over these entrenched, repeat-dose treatments to gain adoption.

What stocks are similar to Intellia Therapeutics, Inc. (NTLA)?

Other names that sit close to NTLA: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Intellia Therapeutics, Inc. (NTLA)

There are three common ways to get NTLA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NTLA sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NTLA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics is a pre-commercial gene-editing company whose value is concentrated in a small number of late-stage programs that have not yet reached the market. The nearest hard date is March 10, 2027, when the FDA is scheduled to decide on lonvo-z under Priority Review. If you believe in vivo CRISPR editing will become a durable treatment modality and that lonvo-z and nex-z can clear regulatory review and launch successfully over the next few years, the relevant questions become position sizing and overlap with other speculative biotech holdings, not timing. The opposing case is that any single clinical setback, regulatory delay, or safety signal could sharply reduce the stock's value, and that continued cash burn means shareholders face ongoing dilution risk before the company ever earns a profit.

More on Intellia Therapeutics, Inc. (NTLA)

Whether NTLA is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NTLA a buy or a sell?, and where the stock could go from here in the NTLA stock forecast.

For income investors, whether NTLA pays a dividend and how the payout looks is covered in does NTLA pay a dividend? And to weigh NTLA against a peer, read the full side-by-side comparisons: NTLA vs BEAM and NTLA vs CRSP.

Wondering how NTLA fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Intellia Therapeutics, Inc.

Ask Walnut's AI anything about NTLA and see how it fits what you own.

FAQ

What does Intellia do?

+

Intellia Therapeutics is a clinical-stage biotechnology company that develops genome-editing medicines using CRISPR/Cas9. Its specialty is in vivo editing, delivering the editing machinery directly into the body so a single dose can permanently alter a disease-causing gene. Its two lead programs are lonvo-z for hereditary angioedema and nex-z for ATTR amyloidosis, the latter partnered with Regeneron Pharmaceuticals.

Is NTLA a good stock to buy right now?

+

That depends entirely on an investor's risk tolerance and time horizon, and this is not advice. The bull case is positive Phase 3 lonvo-z data, an FDA filing accepted under Priority Review with a March 10, 2027 decision date, a Regeneron-partnered ATTR program, and a validated in vivo platform; the mean analyst target was about $23 in October 2026. The bear case, which Barclays took when it initiated at underweight with an $8 target, is that NTLA is pre-revenue, unprofitable, loses roughly $95 to $107 million per quarter, and depends on binary trial and regulatory outcomes that can move the stock sharply.

Is NTLA profitable?

+

No. Intellia is a clinical-stage, pre-revenue company that records only collaboration revenue and has no approved products generating sales. It reported a net loss of roughly $96 million in the first quarter of 2026 and about $107 million in the second, about $400 million over the trailing twelve months, and funds operations through cash reserves and periodic equity raises. Profitability would depend on successfully bringing lonvo-z, nex-z, or another program to market, which has not yet happened.

Does NTLA pay a dividend?

+

No. Intellia Therapeutics does not pay a dividend. As an unprofitable, pre-commercial biotech, the company directs all of its capital toward clinical development and operations rather than returning cash to shareholders. Investors seeking dividend income would need to look elsewhere in the healthcare or broader market, as any return from NTLA would have to come from share-price appreciation.

What is the difference between lonvo-z and nex-z?

+

Both are in vivo CRISPR therapies but target different diseases. Lonvo-z (formerly NTLA-2002) is for hereditary angioedema and is wholly described by Intellia; it reported positive Phase 3 HAELO results in 2026, and the FDA accepted its application under Priority Review with a March 10, 2027 decision date. Nex-z (formerly NTLA-2001) targets ATTR amyloidosis, is developed with Regeneron, and is in the Phase 3 MAGNITUDE and MAGNITUDE-2 trials after the FDA lifted earlier clinical holds.

How much cash does Intellia have and what is its runway?

+

Intellia reported approximately $517 million in cash, cash equivalents, and marketable securities as of March 31, 2026, and an April 2026 equity offering added roughly $207 million in gross proceeds. Management stated this was expected to fund operations at least into 2028. By June 30, 2026, Yahoo Finance data showed about $438 million of cash and short-term investments, and in September 2026 Intellia added a debt facility of up to $400 million from OrbiMed, with $75 million upfront. Because the company loses roughly $95 to $107 million per quarter, additional capital raises before reaching profitability remain likely.

Who are Intellia's main competitors?

+

The closest pure-play peers are CRISPR Therapeutics (CRSP), which has an approved CRISPR product, and Editas Medicine (EDIT). Beam Therapeutics (BEAM) competes with base editing. In Intellia's target diseases, nex-z would face approved ATTR therapies from Alnylam, Pfizer, and BridgeBio, while lonvo-z would face established hereditary angioedema prophylaxis from companies such as Takeda and CSL.

What is the biggest risk of investing in NTLA?

+

The biggest risk is the binary, pre-revenue nature of the business. Intellia's value is concentrated in a few late-stage programs, so a failed trial, safety signal, or regulatory delay for lonvo-z or nex-z could sharply reduce the stock. The company is also unprofitable and burns cash, meaning shareholders face ongoing dilution risk from future equity raises before any product ever turns a profit.

When will the FDA decide on lonvo-z?

+

The FDA accepted Intellia's biologics license application for lonvo-z in hereditary angioedema under Priority Review and set a decision date of March 10, 2027. Approval would make it Intellia's first commercial product and one of the first in vivo CRISPR therapies on the market. A rejection or delay would hit the stock hard, since lonvo-z is the nearest path to product revenue.

How has NTLA stock performed in 2026?

+

NTLA closed at about $11.19 on October 16, 2026, up about 22% year to date but down about 55% over the past year, after trading between about $7.95 and $28.25 over 52 weeks. The stock has been volatile around regulatory and financing news, including a 7.6% one-day gain in early October 2026. Walnut is not an investment adviser, and past moves do not predict future ones.

How did Intellia do in its latest quarter?

+

In the second quarter of 2026 Intellia reported collaboration revenue of about $7.7 million, down about 46% year over year, and a net loss of about $107 million, or -$0.80 per share against a consensus estimate of -$0.78. The next report is expected around November 5, 2026, with analysts looking for a loss near -$0.79 per share.

Guides that feature NTLA

NTLA is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Intellia Therapeutics, Inc.'s investor relations page or your broker before making investment decisions.